vs
AGENUS INC（AGEN）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
AGENUS INC的季度营收约是Aligos Therapeutics, Inc.的202.4倍（$34.2M vs $169.0K）。AGENUS INC净利率更高（-31.0% vs -11763.9%，领先11732.9%）。AGENUS INC同比增速更快（27.5% vs -72.1%）。过去两年AGENUS INC的营收复合增速更高（10.5% vs -50.7%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
AGEN vs ALGS — 直观对比
营收规模更大
AGEN
是对方的202.4倍
$169.0K
营收增速更快
AGEN
高出99.6%
-72.1%
净利率更高
AGEN
高出11732.9%
-11763.9%
两年增速更快
AGEN
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $169.0K |
| 净利润 | $-10.6M | $-19.9M |
| 毛利率 | — | — |
| 营业利润率 | 42.1% | -12907.7% |
| 净利率 | -31.0% | -11763.9% |
| 营收同比 | 27.5% | -72.1% |
| 净利润同比 | 77.3% | 75.8% |
| 每股收益（稀释后） | $0.09 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENALGS
| Q4 25 | $34.2M | $169.0K | ||
| Q3 25 | $30.2M | $741.0K | ||
| Q2 25 | $25.7M | $965.0K | ||
| Q1 25 | $24.1M | $311.0K | ||
| Q4 24 | $26.8M | $606.0K | ||
| Q3 24 | $25.1M | $1.3M | ||
| Q2 24 | $23.5M | $1.1M | ||
| Q1 24 | $28.0M | $694.0K |
净利润AGENALGS
| Q4 25 | $-10.6M | $-19.9M | ||
| Q3 25 | $63.9M | $-31.5M | ||
| Q2 25 | $-30.0M | $-15.9M | ||
| Q1 25 | $-26.4M | $43.1M | ||
| Q4 24 | $-46.8M | $-82.2M | ||
| Q3 24 | $-67.2M | $-19.3M | ||
| Q2 24 | $-54.8M | $5.1M | ||
| Q1 24 | $-63.5M | $-34.9M |
毛利率AGENALGS
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
营业利润率AGENALGS
| Q4 25 | 42.1% | -12907.7% | ||
| Q3 25 | -15.0% | -3827.4% | ||
| Q2 25 | -65.0% | -1924.0% | ||
| Q1 25 | -55.3% | -6187.5% | ||
| Q4 24 | -96.5% | -3393.2% | ||
| Q3 24 | -125.5% | -1610.5% | ||
| Q2 24 | -128.4% | -2489.5% | ||
| Q1 24 | -117.4% | -3176.7% |
净利率AGENALGS
| Q4 25 | -31.0% | -11763.9% | ||
| Q3 25 | 211.4% | -4256.0% | ||
| Q2 25 | -116.8% | -1643.8% | ||
| Q1 25 | -109.6% | 13854.7% | ||
| Q4 24 | -174.4% | -13556.1% | ||
| Q3 24 | -267.7% | -1540.7% | ||
| Q2 24 | -233.1% | 477.0% | ||
| Q1 24 | -226.6% | -5023.5% |
每股收益（稀释后）AGENALGS
| Q4 25 | $0.09 | $4.23 | ||
| Q3 25 | $1.94 | $-3.04 | ||
| Q2 25 | $-1.00 | $-1.53 | ||
| Q1 25 | $-1.03 | $-2.11 | ||
| Q4 24 | $-1.95 | $-13.10 | ||
| Q3 24 | $-3.08 | $-3.07 | ||
| Q2 24 | $-2.52 | $0.81 | ||
| Q1 24 | $-3.04 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $77.8M |
| 总债务越低越好 | $44.7M | — |
| 股东权益账面价值 | $-271.1M | $53.5M |
| 总资产 | $226.8M | $88.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AGENALGS
| Q4 25 | $3.0M | $77.8M | ||
| Q3 25 | $3.5M | $99.1M | ||
| Q2 25 | $9.5M | $122.9M | ||
| Q1 25 | $18.5M | $137.9M | ||
| Q4 24 | $40.4M | $56.9M | ||
| Q3 24 | $44.8M | $74.9M | ||
| Q2 24 | $93.7M | $94.5M | ||
| Q1 24 | $52.9M | $112.7M |
总债务AGENALGS
| Q4 25 | $44.7M | — | ||
| Q3 25 | $34.2M | — | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGENALGS
| Q4 25 | $-271.1M | $53.5M | ||
| Q3 25 | $-274.1M | $71.8M | ||
| Q2 25 | $-354.6M | $101.9M | ||
| Q1 25 | $-341.8M | $116.4M | ||
| Q4 24 | $-326.4M | $-29.0M | ||
| Q3 24 | $-292.3M | $50.1M | ||
| Q2 24 | $-241.3M | $67.2M | ||
| Q1 24 | $-201.4M | $59.8M |
总资产AGENALGS
| Q4 25 | $226.8M | $88.5M | ||
| Q3 25 | $233.9M | $109.8M | ||
| Q2 25 | $185.2M | $134.7M | ||
| Q1 25 | $200.2M | $150.7M | ||
| Q4 24 | $226.3M | $70.1M | ||
| Q3 24 | $238.5M | $88.4M | ||
| Q2 24 | $292.4M | $108.8M | ||
| Q1 24 | $256.6M | $127.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AGENALGS
| Q4 25 | $-16.6M | $-21.7M | ||
| Q3 25 | $-14.7M | $-24.3M | ||
| Q2 25 | $-20.2M | $-15.5M | ||
| Q1 25 | $-25.6M | $-20.9M | ||
| Q4 24 | $-28.7M | $-18.4M | ||
| Q3 24 | $-53.3M | $-20.1M | ||
| Q2 24 | $-38.2M | $-19.5M | ||
| Q1 24 | $-38.2M | $-22.7M |
自由现金流AGENALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.2M | — | ||
| Q1 25 | $-25.6M | — | ||
| Q4 24 | $-28.7M | — | ||
| Q3 24 | $-53.3M | — | ||
| Q2 24 | $-38.6M | — | ||
| Q1 24 | $-38.2M | — |
自由现金流率AGENALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -78.7% | — | ||
| Q1 25 | -106.5% | — | ||
| Q4 24 | -107.0% | — | ||
| Q3 24 | -212.2% | — | ||
| Q2 24 | -164.4% | — | ||
| Q1 24 | -136.5% | — |
资本支出强度AGENALGS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 0.1% | — |
现金转化率AGENALGS
| Q4 25 | — | — | ||
| Q3 25 | -0.23× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
